Eli Lilly (LLY) is trading at $1,369.97, below its short-term moving averages after a 2.52% 24-hour decline, but the broader structure still shows a constructive trend above the 50-day average. Fre...
Eli Lilly (LLY) is easing off recent highs rather than breaking down outright. The stock is at $1,369.97, down 2.52% over 24 hours, and it has slipped under the 7-day SMA of $1,414.69, the 20-day SMA of $1,407.70 and the 12-day EMA of $1,403.69. But it remains above the 50-day SMA of $1,303.14, which keeps the medium-term trend intact.
That matters because this looks more like a digestion phase than a trend failure. The volume backdrop supports that read: activity is running at 0.51x the 5-day average, which points to a low-volume pullback rather than an aggressive liquidation.
The company’s latest reported quarter was a clear step up. According to Eli Lilly’s October 29, 2026 release, third-quarter revenue rose 39% year over year to $24.4 billion, driven primarily by Mounjaro and Zepbound. Reported EPS increased 16% to $7.22, while non-GAAP EPS rose 7% to $7.48. Lilly also lifted the midpoint of its 2026 full-year revenue guidance by $5.5 billion to a range of $91.0 billion to $92.0 billion, which gives investors a stronger operating base to lean on.
That backdrop is why the street remains constructive despite the share-price strength already on the chart. RBC Capital reiterated an Outperform rating and a $1,600 price target on November 17, saying the December 7 Innovation Day is strategically important for highlighting growth beyond obesity.
Source link







